Whether the drug and non-drug, cultivated and wild types of Cannabis constitute a single, highly variable species, or the genus is polytypic with more than one species, has been a subject of debate for well over two centuries. This is a contentious issue because there is no universally accepted definition of a species. One widely applied criterion for species recognition is that species are "groups of actually or potentially interbreeding natural populations which are reproductively isolated from other such groups." Populations that are physiologically capable of interbreeding, but morphologically or genetically divergent and isolated by geography or ecology, are sometimes considered to be separate species. Physiological barriers to reproduction are not known to occur within Cannabis, and plants from widely divergent sources are interfertile. However, physical barriers to gene exchange (such as the Himalayan mountain range) might have enabled Cannabis gene pools to diverge before the onset of human intervention, resulting in speciation. It remains controversial whether sufficient morphological and genetic divergence occurs within the genus as a result of geographical or ecological isolation to justify recognition of more than one species.
Most human studies of CBD have been done on people who have seizures, and the FDA recently approved the first CBD-based drug, Epidiolex, for rare forms of epilepsy. Clinical trials for other conditions are promising, but tiny. In one Brazilian study published in 2011 of people with generalized social anxiety disorder, for example, taking a 600-mg dose of CBD (higher than a typical dose from a tincture) lessened discomfort more than a placebo, but only a dozen people were given the pill.
Designed to provide the optimum absorption of CBD into the blood stream by employing a patented slow release delivery system. It’s well accepted that CBD is most effective when taken sublingualy, however most oils when taken in this way are swallowed and broken down by your body. The Gel-Tab™. is placed under the tongue and the CBD is slowly absorbed resulting in higher rates of CBD being absorbed than what would be achieved with a normal oil
Some of the research focuses that were explored in 2018 were: comparison of various agronomic factors on industrial hemp (planting dates, tillage regimens, range of soil fertility, etc.); hemp variety comparison for suitability to PA growing conditions; study of the effectiveness of potential herbicide products; comparison of hemp’s capability for weed suppression to other crops; surveying hemp crops for presence of arthropod and disease pests; evaluation of hemp’s performance for phytoremediation and land reclamation; study of hemp seed oil processing and marketability; development of industrial hemp products (using grain, stalks and flowers); genetic selection for desired hemp variety characteristics; and evaluations of hemp as an animal feed ingredient (cattle).
Anybody can apply to grow industrial hemp except one who has been convicted of a felony for controlled substance in the past 10 years. Anyone who has been issued a hemp license can grow on the approved growing areas indicated on their application. Licensed industrial hemp can be grown anywhere, indoor or outdoor. The research pilot program allows for any size growing area, from large acre lots to small garden sizes. There are no zoning requirements for a hemp license.
A short-term Advisory Board has been appointed to serve through the development of the rules and regulations. The rules and regulations themselves will identify the guidelines for formation of the Advisory Board, so upon adoption of the rules and regulations an Advisory Board will be created which will continue on a regular basis beyond that point.
Marijuana regulators in Washington State will entertain sweeping changes to how marijuana is tested, processed, packaged and sold in one of the U.S.’s oldest recreational marijuana markets, officials announced late Wednesday. Recreational cannabis has been sold in regulated retail outlets in Washington since 2014. Consumers there pay one of the country’s highest tax burdens, generating … Continue reading Washington State Prepares To Rewrite Marijuana Testing And Packaging Rules
"Right now, any claims and dosing recommendations by any company making a CBD product for the medical marijuana market is purely anecdotal," he says. "Asking 100 people who use your product whether they feel better isn't real science. The products on the market are also different from what was used in the scientific studies that they are basing their claims upon. If a study found an anti-anxiety effect when dosing humans with synthetic CBD, that doesn't mean that your CBD oil that contains 18 percent CBD is going to reduce anxiety. It might even have the opposite effect."
Cannabis lowers the pressure in the eye that causes optic nerve damage leading to glaucoma. Research has shown conclusively that marijuana users experience lower internal eye pressure while the body metabolizes THC. However, the psychoactive side effects of using THC to treat glaucoma make cannabis a nonviable medication for most people with the disease.
Cannabis Ruderalis – Thought to be a cannabis species originating in central Asia, it flowers earlier, is much smaller, and can withstand much harsher climates than either Cannabis indica or Cannabis sativa. This species purportedly buds based on age rather than changes in length of daylight, known as auto-flowering. It’s used primarily for food production, such as hemp seeds and hemp seed oil.
Prescription medicine (Schedule 4) for therapeutic use containing 2 per cent (2.0%) or less of other cannabinoids commonly found in cannabis (such as ∆9-THC). A schedule 4 drug under the SUSMP is Prescription Only Medicine, or Prescription Animal Remedy – Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription.
Get Best CBD Oil